LINC01287
The lncRNA LINC01287 is correlated with poor clinical outcome and may function as a novel prognostic biomarker and therapeutic target in the development of antineoplastic therapies for breast cancer (BC).[1]
Contents
Annotated Information
Name
Approved symbol:LINC01287
Approved name:long intergenic non-protein coding RNA 1287
HGNC ID HGNC:50351
Alias symbol:TCONS_l2_00027522
RefSeq ID:NR_125776
LncBook ID:https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0131038
Characteristics
Please input information here.[1]
Function
Si-LINC01287 transfection significantly inhibited the proliferation and metastasis of BC cells, and further promoted apoptosis. Besides, the knockdown of LINC01287 suppressed Wnt/β-catenin activation and affected the expressions of β-catenin, cyclin D1, and c-myc.[1].
Regulation
LINC01287 transfection significantly inhibited the proliferation and metastasis of BC cells, and further promoted apoptosis. [1]
Expression
The levels of LINC01287 were significantly upregulated in BC tissues and BC cell lines, and the abnormal expressions of LINC01287 were correlated with TNM stage and lymph node metastasis. [1]
Diseases
Breast cancer (BC).[1]
Labs working on this lncRNA
- Department of Oncology, The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. sun2uunl1@aliyun.com.[1]
